The US FDA has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Wednesday 15, June 2022. The committee will meet in open session to discuss an Emergency Use Authorization (EUA) request made by Moderna for a COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age.